Literature DB >> 29631414

Comparative Assessment of Small and Large Intestine Biopsies for Ex Vivo HIV-1 Pathogenesis Studies.

Julie Elliott1, Jennifer A Fulcher2,3, F Javier Ibarrondo2, Karen Tanner1, Ian McGowan4,5, Peter A Anton1,3.   

Abstract

Ex vivo mucosal explants have become a mainstay of HIV-1 studies using human tissue. In this study, we examine the baseline phenotypic and virologic differences between biopsies derived from the small intestine (SI) and large intestine (LI) for use in ex vivo explant studies. To do this, we collected endoscopic mucosal biopsies from both SI and LI from the same healthy, HIV-seronegative participants. Mucosal mononuclear cell phenotypes and quantity were compared using flow cytometry. Comparative HIV-1 infectibility of the explants was assessed using an ex vivo explant HIV-1 infection assay. We found that all biopsies had similar numbers of T cells per biopsy. While the percentage of CD4+ T cells from SI biopsies expressed significantly more activation markers (CD38, HLA-DR) and HIV coreceptors (CXCR4, CCR5), the absolute numbers of activated CD4+ T cells were similar between both sites. LI explants, however, supported more efficient HIV-1 infection, as evidenced by earlier rise in p24 accumulation and greater percent of infected explants at limiting infectious doses. These results suggest that explants from LI biopsies support more efficient HIV-1 infection than SI biopsies, despite similar numbers of available, activated HIV-1 target cells. These findings highlight important differences in LI and SI explants, which must be considered in designing and interpreting ex vivo HIV-1 infection studies, and suggest that factors within the tissue other than target cell number and activation state may play a role in regulating HIV-1 infection.

Entities:  

Keywords:  HIV-1 infection; intestinal mucosa; large intestine; small intestine

Mesh:

Substances:

Year:  2018        PMID: 29631414      PMCID: PMC6204566          DOI: 10.1089/AID.2017.0249

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  29 in total

1.  Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants.

Authors:  Carolina Herrera; Martin Cranage; Ian McGowan; Peter Anton; Robin J Shattock
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

2.  Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.

Authors:  Nicola Richardson-Harman; Christine Mauck; Ian McGowan; Peter Anton
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-20       Impact factor: 2.205

3.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.

Authors:  Joseph J Mattapallil; Daniel C Douek; Brenna Hill; Yoshiaki Nishimura; Malcolm Martin; Mario Roederer
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

4.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

Authors:  R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

5.  Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells.

Authors:  P U Cameron; P S Freudenthal; J M Barker; S Gezelter; K Inaba; R M Steinman
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

6.  Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection.

Authors:  Zhi-Qiang Zhang; Stephen W Wietgrefe; Qingsheng Li; Marta Dykhuizen Shore; Lijie Duan; Cavan Reilly; Jeffrey D Lifson; Ashley T Haase
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-02       Impact factor: 11.205

Review 7.  Gut biogeography of the bacterial microbiota.

Authors:  Gregory P Donaldson; S Melanie Lee; Sarkis K Mazmanian
Journal:  Nat Rev Microbiol       Date:  2015-10-26       Impact factor: 60.633

8.  Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.

Authors:  Patricia S Fletcher; Julie Elliott; Jean-Charles Grivel; Leonid Margolis; Peter Anton; Ian McGowan; Robin J Shattock
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

9.  T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols.

Authors:  Gloria Cuevas Preza; Otto O Yang; Julie Elliott; Peter A Anton; Maria T Ochoa
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

10.  Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.

Authors:  Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  3 in total

Review 1.  The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models.

Authors:  Carolina Herrera
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

2.  Complement opsonization of HIV affects primary infection of human colorectal mucosa and subsequent activation of T cells.

Authors:  Esaki M Shankar; Sofia Nyström; Pradyot Bhattacharya; Rada Ellegård; Mohammad Khalid; Cecilia Svanberg; Melissa Govender; Åsa V Keita; Johan D Söderholm; Pär Myrelid; Marie Larsson
Journal:  Elife       Date:  2020-09-02       Impact factor: 8.140

3.  Ex vivo rectal explant model reveals potential opposing roles of Natural Killer cells and Marginal Zone-like B cells in HIV-1 infection.

Authors:  S Abigail Smith; Phillip M Murray; Praveen Kumar Amancha; Cassie G Ackerley; Yi-Juan Hu; Rama R Amara; Colleen F Kelley
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.